S
Selektx
SelekTx develops highly selective biologic drugs called Selektides using an engineered protein scaffold and a combinatorial discovery platform. This approach targets difficult-to-drug receptors, like GPCRs, to create therapeutics with reduced side effects and enhanced stability. The company translates platform innovation into development-ready therapeutic candidates for preclinical advancement.
Traction –/10
HQ unknown
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- SelekTx develops highly selective biologic drugs called Selektides using an engineered protein scaffold and a combinatorial discovery platform. This approach targets difficult-to-drug receptors, like GPCRs, to create therapeutics with reduced side effects and enhanced stability. The company translates platform innovation into development-ready therapeutic candidates for preclinical advancement.